NCT05012982 Immunometabolic Mechanisms of Blood Flow Restriction (BFR) Training After Anterior Cruciate Ligament Reconstruction
| NCT ID | NCT05012982 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Yale University |
| Condition | Anterior Cruciate Ligament Reconstruction |
| Study Type | INTERVENTIONAL |
| Enrollment | 20 participants |
| Start Date | 2023-02-16 |
| Primary Completion | 2026-05 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 20 participants in total. It began in 2023-02-16 with a primary completion date of 2026-05.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This is a crossover phase 4 study to evaluate the impact of blood flow restriction on immunometabolism and gene expression in immune cells in individuals undergoing rehabilitation from anterior cruciate ligament reconstruction.
Eligibility Criteria
Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for two study visits at least 1 week apart 3. All genders, between 18 and 60 years of age 4. In good general health without any underlying medical conditions or prior injury that would place the subject at risk of further injury/illness by participating in the study Exclusion Criteria: 1. Serious medical conditions including cardiovascular, metabolic (diabetes), rheumatologic, pulmonary, or musculoskeletal. 2. Multiple ligament ruptures or trauma 3. Rheumatoid arthritis or other significant comorbidities 4. Lower extremity vascular pathology, including history of deep vein thrombosis 5. Those with a history of sickle cell trait or disease 6. Use of anticoagulant medications 7. Pregnancy 8. Treatment with another investigational drug or other intervention within one month of Study Day 1 9. Current smoker or tobacco use within 3 months of Study Day 1 10. Febrile illness within 2 weeks of Study Day 1
Contact & Investigator
Rachel Perry, PhD
PRINCIPAL INVESTIGATOR
Yale University
Frequently Asked Questions
Who can join the NCT05012982 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 60 Years, studying Anterior Cruciate Ligament Reconstruction. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05012982 currently recruiting?
Yes, NCT05012982 is actively recruiting participants. Contact the research team at rachel.perry@yale.edu for enrollment information.
Where is the NCT05012982 trial being conducted?
This trial is being conducted at Milford, United States, North Haven, United States.
Who is sponsoring the NCT05012982 clinical trial?
NCT05012982 is sponsored by Yale University. The principal investigator is Rachel Perry, PhD at Yale University. The trial plans to enroll 20 participants.